Clinical Trial Update: A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma. [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating YL201 in combination with toripalimab, with or without cisplatin, for recurrent or metastatic nasopharyngeal carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Toripalimab (Toripalimab)
• YL201

Snippet

Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. | Conditions: Recurrent or Metastatic Nasopharyngeal Carcinoma | Phase 1, Phase 2 | Status: RECRUITING